Want to join the conversation?
$LLY and AstraZeneca said they received U.S. Food and Drug Administration (FDA) Fast Track designation for development program in Alzheimer's disease for AZD3293, oral beta secretase cleaving enzyme (BACE) inhibitor now in phase 3 clinical trials. $LLY and AstraZeneca also announced planned initiation of second phase 3 trial for AZD3293.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!